Population-based outcomes for small cell lung cancer: Impact of standard management policies in British Columbia

Lung Cancer

Volumn 43, Issue 1, 2004, Pages 7-16

  Laskin, Janessa J ^a,b   Erridge, Sara C ^a,b   Coldman, Andrew J ^a,b   D'Yachkova, Yulia ^a   Speers, Caroline ^a   Westeel, Virginie ^a   Hislop, T Greg ^a,b   Olivotto, Ivo A ^a,b   Murray, Nevin ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Population based outcomes; Practice guidelines; Small cell lung cancer

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; HEALTH CARE POLICY; HUMAN; LUNG SMALL CELL CANCER; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; STANDARD; TREATMENT OUTCOME;

EID: 0347931827     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.07.004     Document Type: Article

References (29)

1. Sambrook R.J., Girling D.J. A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom. Br. J. Cancer. 84:2001;1447-1452.
2. Richardson G.E., Thursfield V.J., Giles G.G. Reported management of lung cancer in Victoria in 1993: comparison with best practice. Anti-Cancer Council of Victoria Lung Cancer Study Group. Med. J. Aust. 172:2000;321-324.
3. Palmer M.J., O'Sullivan B., Steele R. Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study. Radiother. Oncol. 19:1990;17-28.
4. Pujol J.L., Carestia L., Daures J.P. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br. J. Cancer. 83:2000;8-15.
5. Pignon J.P., Arriagada R., Ihde D.C.et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. 327:1992;1618-1624.
6. Seifter E.J., Ihde D.C. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin. Oncol. 15:1988;278-299.
7. Murray N., Coy P., Pater J.L.et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 11:1993;336-344.
8. Perez C.A., Einhorn L., Oldham R.K.et al. Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. J. Clin. Oncol. 2:1984;1200-1208.
9. Turrisi A.T. III, Glover D.J., Mason B.A. A preliminary report: concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 15:1988;183-187.
10. Bunn P.A. Jr., Lichter A.S., Makuch R.W.et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial. Ann. Intern. Med. 106:1987;655-662.
11. Livingston R.B. Combined modality therapy of lung cancer. Clin. Cancer Res. 3:1997;2638-2647.
12. McCracken J.D., Janaki L.M., Crowley J.J.et al. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. J. Clin. Oncol. 8:1990;892-898.
13. Thomas C.R. Jr., Giroux D.J., Janaki L.M.et al. Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer. Lung Cancer. 33:2001;213-219.
14. Chute J.P., Chen T., Feigal E.et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. Journal of Clinical Oncology. 17:1999;1794-1801.
15. Davis S., Wright P.W., Schulman S.F.et al. Long-term survival in small-cell carcinoma of the lung: a population experience. J. Clin. Oncol. 3:1985;80-91.
16. Albain K.S., Crowley J.J., LeBlanc M.et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J. Clin. Oncol. 8:1990;1563-1574.
17. Cottin V., Arpin D., Lasset C.et al. Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole. Ann. Oncol. 10:1999;809-815.
18. Sawka C., Olivotto I., Coldman A.et al. The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. British Columbia/Ontario Working Group. Br. J. Cancer. 75:1997;1534-1542.
19. Gregor A., Thomson C.S., Brewster D.H.et al. Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study. Thorax. 56:2001;212-217.
20. Kesson E., Bucknall C.E., McAlpine L.G.et al. Lung cancer-management and outcome in Glasgow, 1991-92. Br. J. Cancer. 78:1998;1391-1395.
21. Watkin S.W., Hayhurst G.K., Green J.A. Time trends in the outcome of lung cancer management: a study of 9,090 cases diagnosed in the Mersey Region, 1974-86. Br. J. Cancer. 61:1990;590-596.
22. Janssen-Heijnen M.L., Schipper R.M., Klinkhamer P.J.et al. Improvement and plateau in survival of small-cell lung cancer since 1975: a population-based study. Ann. Oncol. 9:1998;543-547.
23. Lebitasy M.P., Hedelin G., Purohit A.et al. Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994. Br. J. Cancer. 85:2001;808-815.
24. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother. Rep. Part 3. 4:1973;31-42.
25. Evans W.K., Shepherd F.A., Feld R.et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J. Clin. Oncol. 3:1985;1471-1477.
26. Fukuoka M., Furuse K., Saijo N.et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J. Natl. Cancer Inst. 83:1991;855-861.
27. Auperin A., Arriagada R., Pignon J.P.et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N. Engl. J. Med. 341:1999;476-484.
28. Olivotto A., Coldman A.J., Hislop T.G.et al. Compliance with practice guidelines for node-negative breast cancer. J. Clin. Oncol. 15:1997;216-222.
29. Janssen-Heijnen M.L., Gatta G., Forman D.et al. Variation in survival of patients with lung cancer in Europe, 1985-1989. EUROCARE Working Group. Eur. J. Cancer. 34:1998;2191-2196.